Esperion Therapeutics Inc (NASDAQ:ESPR) – Stock analysts at Jefferies Group increased their Q1 2018 earnings estimates for Esperion Therapeutics in a research report issued to clients and investors on Tuesday. Jefferies Group analyst M. Yee now anticipates that the biopharmaceutical company will post earnings per share of ($1.42) for the quarter, up from their previous estimate of ($1.95). Jefferies Group also issued estimates for Esperion Therapeutics’ Q2 2018 earnings at ($1.38) EPS, Q3 2018 earnings at ($1.35) EPS, Q4 2018 earnings at ($1.36) EPS and FY2018 earnings at ($5.51) EPS.
Esperion Therapeutics (NASDAQ:ESPR) last announced its quarterly earnings results on Tuesday, February 20th. The biopharmaceutical company reported ($1.44) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.80) by $0.36. During the same period last year, the business earned ($1.29) EPS.
Other equities research analysts have also issued reports about the company. Northland Securities restated a “buy” rating and set a $72.00 price target on shares of Esperion Therapeutics in a research note on Friday, November 10th. Bank of America upgraded Esperion Therapeutics from a “neutral” rating to a “buy” rating and set a $76.00 price target for the company in a research note on Friday, January 5th. BidaskClub upgraded Esperion Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, December 16th. UBS Group set a $88.00 price target on Esperion Therapeutics and gave the stock a “buy” rating in a research note on Wednesday, January 17th. Finally, Stifel Nicolaus set a $105.00 price target on Esperion Therapeutics and gave the stock a “buy” rating in a research note on Monday, January 15th. Seven investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have issued a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $79.54.
Shares of Esperion Therapeutics (NASDAQ ESPR) opened at $78.90 on Friday. The company has a market capitalization of $2,120.00, a PE ratio of -11.24 and a beta of 2.64. Esperion Therapeutics has a 12 month low of $20.39 and a 12 month high of $82.18.
Several hedge funds and other institutional investors have recently modified their holdings of the company. MetLife Investment Advisors LLC purchased a new stake in shares of Esperion Therapeutics in the fourth quarter worth about $496,000. Iguana Healthcare Management LLC boosted its position in shares of Esperion Therapeutics by 10.0% in the fourth quarter. Iguana Healthcare Management LLC now owns 165,000 shares of the biopharmaceutical company’s stock worth $10,864,000 after buying an additional 15,000 shares during the period. BB&T Securities LLC purchased a new stake in shares of Esperion Therapeutics in the fourth quarter worth about $263,000. Millennium Management LLC boosted its position in shares of Esperion Therapeutics by 1,062.7% in the fourth quarter. Millennium Management LLC now owns 387,947 shares of the biopharmaceutical company’s stock worth $25,542,000 after buying an additional 354,580 shares during the period. Finally, Teachers Advisors LLC boosted its position in shares of Esperion Therapeutics by 3.8% in the fourth quarter. Teachers Advisors LLC now owns 148,407 shares of the biopharmaceutical company’s stock worth $9,771,000 after buying an additional 5,426 shares during the period. 87.67% of the stock is owned by institutional investors.
In other news, Director Nicole Vitullo sold 9,326 shares of the company’s stock in a transaction dated Wednesday, December 6th. The stock was sold at an average price of $53.85, for a total value of $502,205.10. Following the completion of the sale, the director now owns 2,472 shares of the company’s stock, valued at $133,117.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 32.50% of the stock is owned by corporate insiders.
ILLEGAL ACTIVITY NOTICE: “Esperion Therapeutics Inc (ESPR) to Post Q1 2018 Earnings of ($1.42) Per Share, Jefferies Group Forecasts” was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this report on another site, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The legal version of this report can be accessed at https://www.dispatchtribunal.com/2018/02/25/esperion-therapeutics-inc-espr-to-post-q1-2018-earnings-of-1-42-per-share-jefferies-group-forecasts.html.
Esperion Therapeutics Company Profile
Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.
Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.